FDA-cleared profile

InVision Precision LVEF (LVEF)

InVision Medical Technology Corporation · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Assist sonographers and physicians in cardiac evaluation by providing an automated LVEF estimate from previously acquired transthoracic cardiac ultrasound images in patients aged 22 years and older.

Clinical role
Post-acquisition semi-automatic LVEF measurement aid; it selects views, provides editable LV segmentation, recalculates EF after user edits, and supports user confirmation or rejection.
Images and patients
Ultrasound · Heart, including the left ventricle
Key limitation
Keep in mind: The labeled use is previously acquired transthoracic cardiac ultrasound in patients aged 22 years and older. The clinician can modify the segmentation and downstream LVEF before finalization; the FDA packet describes an assistive cardiac-evaluation measurement and does not establish autonomous clinical decision-making or use outside the specified input.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Assist sonographers and physicians in cardiac evaluation by providing an automated LVEF estimate from previously acquired transthoracic cardiac ultrasound images in patients aged 22 years and older.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Heart, including the left ventricle Input: Previously acquired transthoracic cardiac ultrasound images or DICOM clips from ultrasound or data-collection equipment uploaded to a compatible PACS; single-view or biplane input is described, and the labeled population is patients aged 22 years and older.
  • Who uses it?Intended users: Sonographers and physicians evaluating cardiac ultrasound
  • What does the software produce?Output: An automated numerical LVEF estimate with semi-automatic LV segmentations shown as adjustable annotations with the video clip; the EF calculation updates in real time after user modification and the result can be confirmed or rejected.
  • What is its most important limitation?Key limitation: The labeled use is previously acquired transthoracic cardiac ultrasound in patients aged 22 years and older. The clinician can modify the segmentation and downstream LVEF before finalization; the FDA packet describes an assistive cardiac-evaluation measurement and does not establish autonomous clinical decision-making or use outside the specified input.

Clinical takeaway. Clinical role: Assist sonographers and physicians in cardiac evaluation by providing an automated LVEF estimate from previously acquired transthoracic cardiac ultrasound images in patients aged 22 years and older.

Evidence takeaway. Evidence from the reviewed source record: FDA K232331 reports a retrospective multicenter performance evaluation using input from Philips, GE, and Siemens. The FDA summary reports mean RMSD of about 6.06 for biplane, 6.17 for A4C, and 7.12 for A2C, with Dice scores of 0.89 for A4C segmentation and 0.90 for A2C segmentation; subgroup analyses covered race or ethnicity, age, gender, BMI, site, equipment, and EF values. The reviewed FDA text does not state a clinical sample size or sensitivity/specificity endpoint.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Assist sonographers and physicians in cardiac evaluation by providing an automated LVEF estimate from previously acquired transthoracic cardiac ultrasound images in patients aged 22 years and older.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Post-acquisition semi-automatic LVEF measurement aid; it selects views, provides editable LV segmentation, recalculates EF after user edits, and supports user confirmation or rejection.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Previously acquired transthoracic cardiac ultrasound images or DICOM clips from ultrasound or data-collection equipment uploaded to a compatible PACS; single-view or biplane input is described, and the labeled population is patients aged 22 years and older.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
An automated numerical LVEF estimate with semi-automatic LV segmentations shown as adjustable annotations with the video clip; the EF calculation updates in real time after user modification and the result can be confirmed or rejected.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Cardiac ultrasound evaluation workflow; facility type is not stated in the FDA packet
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Sonographers and physicians evaluating cardiac ultrasound
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The labeled use is previously acquired transthoracic cardiac ultrasound in patients aged 22 years and older. The clinician can modify the segmentation and downstream LVEF before finalization; the FDA packet describes an assistive cardiac-evaluation measurement and does not establish autonomous clinical decision-making or use outside the specified input.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K232331 reports a retrospective multicenter performance evaluation using input from Philips, GE, and Siemens. The FDA summary reports mean RMSD of about 6.06 for biplane, 6.17 for A4C, and 7.12 for A2C, with Dice scores of 0.89 for A4C segmentation and 0.90 for A2C segmentation; subgroup analyses covered race or ethnicity, age, gender, BMI, site, equipment, and EF values. The reviewed FDA text does not state a clinical sample size or sensitivity/specificity endpoint.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K232331 reports a retrospective multicenter performance evaluation using input from Philips, GE, and Siemens. The FDA summary reports mean RMSD of about 6.06 for biplane, 6.17 for A4C, and 7.12 for A2C, with Dice scores of 0.89 for A4C segmentation and 0.90 for A2C segmentation; subgroup analyses covered race or ethnicity, age, gender, BMI, site, equipment, and EF values. The reviewed FDA text does not state a clinical sample size or sensitivity/specificity endpoint.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

InVision Precision LVEF (LVEF) regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K232331
  • IndependenceIndependence not established

K232331

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232331. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Previously acquired transthoracic cardiac ultrasound images or DICOM clips from ultrasound or data-collection equipment uploaded to a compatible PACS; single-view or biplane input is described, and the labeled population is patients aged 22 years and older.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K232331: InVision Precision LVEF (LVEF)

  2. Routing

    Source context, not route validation: The software interfaces with data files uploaded to a compatible DICOM-compliant PACS by ultrasound or data-collection equipment and uses an integrated image-view application. Specific PACS interfaces, versions, deployment, and local compatibility are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K232331: InVision Precision LVEF (LVEF)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: An automated numerical LVEF estimate with semi-automatic LV segmentations shown as adjustable annotations with the video clip; the EF calculation updates in real time after user modification and the result can be confirmed or rejected.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K232331: InVision Precision LVEF (LVEF)

  5. Viewer/worklist/report

    Unresolved route: An automated numerical LVEF estimate with semi-automatic LV segmentations shown as adjustable annotations with the video clip; the EF calculation updates in real time after user modification and the result can be confirmed or rejected.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K232331: InVision Precision LVEF (LVEF)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The software interfaces with data files uploaded to a compatible DICOM-compliant PACS by ultrasound or data-collection equipment and uses an integrated image-view application. Specific PACS interfaces, versions, deployment, and local compatibility are not established.
  • Exact FDA submission
  • Checked 2026-09-08
Security
InVision Medical Technology's trust & security page states that InVision maintains an independent SOC 2 Type II attestation audited by Johanson LLP, backed by continuous control monitoring, annual penetration testing and cybersecurity reviews, plus HIPAA safeguards with a BAA, PHI handling and data residency commitments, and a vulnerability disclosure route, covering systems that process customer data.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statements, not attestations. The SOC 2 Type II report is available on request and was not read; the page names InVision generally and does not name InVision Precision LVEF or any specific release; exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for InVision Precision LVEF (LVEF); FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K232331
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Heart, including the left ventricle
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-04-25
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K232331 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K232331: InVision Precision LVEF (LVEF)

    U.S. Food and Drug Administration - Published 2024-04-25 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. InVision Precision LVEF (LVEF) model card (K232331)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K232331

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. InVision Medical Technology: Trust & Security

    InVision Medical Technology Corporation - Accessed 2026-10-27

    Scope: security

Research history

  1. K232331 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260667

Alturion Series Diagnostic Ultrasound System

Philips Ultrasound, LLC

Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Decision
2026-06-29
FDA-cleared K260844

ACUSON Sequoia Diagnostic Ultrasound System;ACUSON Sequoia Select Diagnostic Ultrasound System;ACUSON Origin Diagnostic Ultrasound System;ACUSON Origin ICE Diagnostic Ultrasound System

Siemens Medical Solutions USA, Inc.

Authorized purpose: ACUSON Sequoia, Select, Origin, and Origin ICE diagnostic ultrasound systems acquire and display the labeled fetal, abdominal, pediatric, neonatal, cephalic, small-part, obstetric, cardiac, transesophageal, intracardiac, vascular, and musculoskeletal examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; transesophageal and intracardiac applications
Decision
2026-06-16
FDA-cleared K260300

WatchMate Software

Anumana, Inc.

Authorized purpose: WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.

Modality
Ultrasound
Anatomy
Heart and left atrial appendage
Decision
2026-06-15
FDA-cleared K260780

HeartFocus

Deski

Authorized purpose: Guides medical professionals acquiring ten standard 2D transthoracic echocardiographic views in adults requiring a cardiac ultrasound examination; acquired images require qualified clinical interpretation.

Modality
Ultrasound
Anatomy
Heart/Cardiovascular
Decision
2026-06-03

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history